Composition for preventing or treating cancer comprising fermented extract of stewartia pseudocamellia as active ingredient
A pharmaceutical composition using a fermented lactic acid bacteria extract of the Japanese anthurium effectively targets and kills cancer cells, addressing the inadequacies of current cancer treatments and prevention methods by leveraging the antimicrobial properties of lactic acid bacteria to combat various cancer types.
Patent Information
- Application Number
- PCT/KR2024/006465
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2024-05-13
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for preventing and treating cancer are inadequate, as cancer remains an incurable disease with increasing incidence and mortality rates, particularly due to environmental factors like diet, and existing treatments are often ineffective in early detection and prevention.
A pharmaceutical composition is developed containing a fermented lactic acid bacteria extract of the Japanese anthurium, which is produced by inoculating a lactic acid bacteria culture into an extract of the Japanese anthurium, using strains like Lactobacillus plantarum, Lacticaseibacillus rhamnosus, and Lactiplantibacillus pentosus, and fermenting at 30°C to 37°C for 1 to 6 days, to create a fermented product effective against various types of cancer.
The composition demonstrates significant cancer cell killing effects on blood, colon, breast, and pancreatic cancer cells, offering a potential preventive and treatment option for cancer, with the fermented product showing promise in reducing cancer severity and proliferation.
Smart Images

Figure KR2024006465_28112024_PF_FP_ABST
Abstract
Description
Composition for preventing or treating cancer containing fermented extract of the Korean fir tree as an active ingredient
[0001] This application claims the benefit of Korean Patent Application No. 10-2023-0065282, filed with the Korean Intellectual Property Office on May 19, 2023, the entire contents of which are incorporated herein by reference.
[0002] The present application relates to a method for preparing a composition for preventing or treating cancer, which comprises an extract of the zelkova tree as an active ingredient.
[0003] Cells undergo growth, differentiation, and programmed death (apoptosis), or remain in a state of growth arrest, and these processes are tightly regulated. However, in cancer cells, certain genes become abnormal, altering the properties of the proteins they produce. This, in turn, disrupts cell growth regulation. These abnormalities in cell growth regulation are accompanied by genetic mutations, making cancer a genetic disease caused by genetic abnormalities.
[0004] It is believed that normal cells transform into cancer cells when exposed to risk factors that cause genetic mutations, thus causing cancer. Commonly known risk factors for cancer include smoking, carcinogenic foods and chemicals, and carcinogenic pathogens. When normal cells are exposed, genetic mutations occur. Furthermore, approximately 10-20% of cancer cases are caused by genetic abnormalities inherited from parents. DNA, a component of the cell nucleus, undergoes structural changes that lead to the formation of cancer cells. These mutated cells continue to possess this altered DNA even as they divide, ultimately leading to the development of cancer. These changes do not occur instantaneously; cancer typically develops as a result of the accumulation of various genetic mutations over 20-30 years.
[0005] The human immune system is capable of destroying up to 10 million tumor cells within the body. However, when cancer cells divide and multiply to the point of clinical detection, they typically contain at least 1 billion tumor cells, far exceeding the number that the immune system can destroy. Consequently, cancer cells fail to be eliminated, leading to the development of cancer.
[0006] Cancer is one of the incurable diseases humanity must address. Despite massive investment in research and development to cure it worldwide and innovative advancements in medical technology, the incidence and mortality from cancer continue to rise. According to recent statistics from the World Health Organization, approximately 10 million new cancer cases are diagnosed worldwide annually. In Korea, cancer is the leading cause of death, with over 100,000 new cases diagnosed and over 60,000 deaths annually. In particular, colorectal cancer is the second most common malignant tumor in Korea, and its incidence is steadily increasing.
[0007] There are various factors that contribute to the development of cancer, and they can be categorized into internal factors, such as genetic or immunological factors, and external factors, such as chemicals, radiation, or viruses. In particular, with the recent increase in cancer patients, environmental factors are known to account for a greater proportion of cancer occurrence in modern society than genetic factors. In particular, the rate of cancer caused by diet is known to be very high, accounting for 36% of environmental factors. Specifically, in the case of colon cancer, increased intake of animal fat, sugar, and alcohol, as well as decreased intake of fiber, vegetables, fruits, and antioxidant vitamins, are known to be the main causes.
[0008] Therefore, unless there are fundamental changes in the living environment in modern society, the increasing incidence of cancer and the number of cancer-related deaths are expected to continue. In particular, cancer is nearly impossible to cure if not detected early. As the disease progresses, the suffering and economic losses for patients and their families become enormous. Furthermore, it incurs significant social costs, including the depletion of health insurance funds. This underscores the importance of cancer prevention and early treatment.
[0009] The problem to be solved by the present application is to provide a method for producing a pharmaceutical composition for preventing or treating cancer, which contains a fermented product of the Korean yam tree as an active ingredient.
[0010] The problem to be solved by this application is to provide a pharmaceutical composition for preventing or treating cancer, which contains a lactic acid bacteria fermented extract of the zelkova tree as an active ingredient.
[0011] The problem that this application seeks to solve is to provide a food composition for preventing or improving cancer that contains a lactic acid bacteria fermented extract of the zelkova tree as an active ingredient.
[0012] The problem to be solved by this application is to provide a feed composition for preventing or improving cancer, which contains a lactic acid bacteria fermented extract of the Japanese yam tree as an active ingredient.
[0013] The problem that this application seeks to solve is to provide a pharmaceutical composition for preventing or improving cancer that contains a lactic acid bacteria fermented extract of the zelkova tree as an active ingredient.
[0014] The problem to be solved by the present application is to provide a method for preventing or treating cancer, which comprises a step of administering to a non-human subject a pharmaceutical composition containing a fermented product of the zelkova tree as an active ingredient.
[0015] The problem that this application seeks to solve is to provide a composition containing a fermented product of the zelkova tree as an active ingredient for the prevention or treatment of cancer.
[0016] The problems to be solved by this application are not limited to those mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
[0017] In order to solve the above-described problem, one embodiment of the present application provides a method for preparing a pharmaceutical composition for preventing or treating cancer, comprising the steps of preparing an extract of a Japanese yam tree; and a step of inoculating the extract with a lactic acid bacteria culture solution and fermenting it to obtain a fermented product; wherein the pharmaceutical composition comprises the fermented product as an active ingredient.
[0018] In one embodiment of the present application, the fermented product is a product obtained by fermenting a hot water extract with lactic acid bacteria, and the lactic acid bacteria may be at least one selected from the group consisting of Lactobacillus plantarum, Lacticaseibacillus rhamnosus, and Lactiplantibacillus pentosus.
[0019] In one embodiment of the present application, in the step of obtaining the fermented product, the fermentation may be performed at 30°C to 37°C for 1 to 6 days.
[0020] In one embodiment of the present application, the step of preparing the extract of the zelkova tree may be to extract the powder of the zelkova tree by mixing it with a solvent at a ratio of 1:5 to 1:30.
[0021] In one embodiment of the present application, the zelkova tree may be at least one of a leaf and a stem, and the extract may be an extract obtained by hot water extraction at 80°C to 110°C for 2 to 12 hours.
[0022] In one embodiment of the present application, the cancer is breast cancer, pancreatic cancer, colon cancer, ovarian cancer, stomach cancer, cervical cancer, thyroid cancer, parathyroid cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, bile duct cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head and neck cancer, uterine cancer, rectal cancer, brain cancer, anal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine cancer, endocrine cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureteral cancer, renal cell carcinoma, renal pelvic carcinoma, blood cancer, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, It may be at least one selected from the group consisting of multiple myeloma, chronic lymphocytic leukemia, central nervous system (CNS) tumor, spinal cord tumor, brainstem glioma, and pituitary adenoma.
[0023] One embodiment of the present application provides a pharmaceutical composition for preventing or treating cancer, which is manufactured by the above manufacturing method and includes a lactic acid bacteria fermented extract of a Japanese yam tree as an active ingredient.
[0024] One embodiment of the present application provides a food composition for preventing or improving cancer, comprising a lactic acid bacteria fermented extract of a Japanese yam tree as an active ingredient.
[0025] One embodiment of the present application provides a feed composition for preventing or improving cancer, comprising a lactic acid bacteria fermented extract of a Japanese yam tree as an active ingredient.
[0026] One embodiment of the present application provides a pharmaceutical composition for preventing or improving cancer, comprising a lactic acid bacteria fermented extract of a Japanese yam tree as an active ingredient.
[0027] One embodiment of the present application provides a method for preventing or treating cancer, comprising administering to a subject a pharmaceutical composition comprising a fermented product of the zelkova tree as an active ingredient.
[0028] One embodiment of the present application provides a method for preventing or treating cancer, comprising administering to a subject other than a human a pharmaceutical composition comprising a fermented product of the zelkova tree as an active ingredient.
[0029] One embodiment of the present application provides the use of a composition comprising a lactic acid bacteria fermented extract of a Korean yam tree as an active ingredient for preparing a medicament for preventing or treating cancer.
[0030] One embodiment of the present application provides the use of a composition comprising a lactic acid bacteria fermented extract of a Korean yam tree as an active ingredient for preparing a food for preventing or treating cancer.
[0031] One embodiment of the present application provides the use of a composition comprising a lactic acid bacteria fermented extract of a Korean yam tree as an active ingredient for preparing a feed for preventing or treating cancer.
[0032] One embodiment of the present application provides the use of a composition comprising a lactic acid bacteria fermented extract of a Korean yam tree as an active ingredient for manufacturing a quasi-drug for preventing or treating cancer.
[0033] A composition according to one embodiment of the present application has an effect of killing cancer cells.
[0034] Figure 1 shows the cancer cell killing effect on blood cancer cells (Molt-4).
[0035] Figure 2 shows the cancer cell killing effect on colon cancer cells (HT-29).
[0036] Figure 3 shows the cancer cell killing effect on breast cancer cells (MCF-7).
[0037] Figure 4 shows the cancer cell killing effect on pancreatic cancer cells (MIA PaCa-2).
[0038] Hereinafter, the present application will be described in more detail.
[0039] The specific structural and functional descriptions below are merely examples to explain embodiments according to the concept of the present application, and embodiments according to the concept of the present application may be implemented in various forms and should not be construed as being limited to the embodiments described in this specification.
[0040] Embodiments based on the concepts of this application may be subject to various modifications and take various forms, and thus specific embodiments are described in detail herein. However, this is not intended to limit the embodiments based on the concepts of this application to a specific disclosed form, and it should be understood that all modifications, equivalents, and alternatives fall within the spirit and technical scope of this application.
[0041] The terminology used in this specification is solely for the purpose of describing specific embodiments and is not intended to limit the present application. The singular expression "a," "an," and "the" include the plural expressions unless the context clearly dictates otherwise.
[0042] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which this application pertains. Terms defined in commonly used dictionaries should be interpreted as having a meaning consistent with their meaning in the context of the relevant technology, and will not be interpreted in an idealized or overly formal sense unless explicitly defined herein.
[0043] As used herein, the term "including as an active ingredient" means including an amount sufficient to effect a desired biological effect, such as a beneficial outcome, including but not limited to the prevention, reduction, alleviation, or elimination of signs or symptoms of a disease or disorder. This amount is referred to as an "effective amount." Accordingly, the total amount of each active ingredient of a composition or additive is sufficient to produce a significant individual benefit. Therefore, the effective amount will vary depending on the circumstances under which it is administered.
[0044] The term "improvement" in this application means any action that reduces a parameter associated with the condition being treated by ingestion of the composition, for example, the severity of a symptom.
[0045] The term "prevention" in this application refers to blocking the appearance of a disease or symptoms associated with a disease in an asymptomatic subject at risk of developing the disease due to exposure to a disease agent. It also refers to any action that suppresses or delays the onset of a disease by administering the composition of this application.
[0046] The term "treatment" as used herein refers to an approach to obtaining beneficial or desirable clinical outcomes, including, but not limited to, alleviation of symptoms, reduction in the extent of a disease, stabilization (i.e., not worsening) of a disease, delay or slowing of disease progression, improvement, palliation or alleviation of a disease state, whether or not detectable for the purposes of the present invention.
[0047] Therefore, treatment encompasses both curative and preventative measures, and those requiring treatment include not only existing disease states but also those requiring prevention. Furthermore, it can refer to any action that improves or benefits the symptoms of cancer by administering the pharmaceutical composition of the present invention to a subject.
[0048] Stewartia pseudocamellia Maxim. is a deciduous tree in the Theaceae family. It is distributed throughout South Jeolla Province, North Jeolla Province, South Gyeongsang Province, and North Gyeongsang Province in South Korea. It primarily grows in the Jirisan Mountain area, where it is relatively abundant. This plant grows to a height of 7–15 m and has a blackish-reddish-brown bark, but the bark peels off in circular or long stripes, revealing reddish-yellow markings. The alternate, oval-shaped leaves have fine serrations along their margins. The white flowers bloom in June and July, often alongside the leaves. The flowers are cymes with five petals and numerous stamens. The hard fruit, which ripens in October, is covered with soft hairs. Due to the mottled bark, it is also called the silk tree or brocade tree. The leaves turn yellow in the fall, and the flowers resemble camellias, making it a common ornamental tree in gardens and parks. The wood is hard and is often used for furniture, and is now sought after by many people as a valuable medicinal herb and for drinking tea. The bark peels off in thin pieces and has reddish-brown, grayish-white, and grayish-brown patterns that are mottled. The axils grow at the base of new branches, and the fruit is a pentagonal ovoid capsule. This plant is also known by the synonyms Stewartia koreana Nakai or Stewartia pseudocamellia Maxim. var. koreana (Nakai) Kim, and some believe it is an endemic species because its flowers are cup-shaped and its branches are straight and round. However, it is mainly recorded as Stewartia pseudocamellia Maxim., which is currently distributed in Japan and other countries, and another synonym is Stewartia ptero-petiolata Cheng var. koreana (Rehd.) Sealy.The nopal cactus has large and gorgeous flowers, which are used for ornamental purposes. Its wood is hard and has beautiful patterns, and is used as furniture material, decorative material, etc. The bark and root bark of the tree are called molan, which has the effect of relaxing tendons and activating blood circulation, and can relieve stasis caused by bruises. Its related activities caused by rheumatism have also been studied.
[0049] In this application, the nopal cactus extract can be extracted from various organs of the natural, hybrid or variant plants of the nopal cactus. For example, it can be extracted from the seeds, roots, above-ground parts, stems, leaves, flowers, fruit bodies, fruit skins of the nopal cactus, as well as from plant tissue cultures. Without being limited thereto, the nopal cactus extract may be at least one of the stem extract and leaf extract of the nopal cactus.
[0050] In this application, the term "extract" has the meaning commonly used as "crude extract" in the art, but broadly includes fractions obtained by further fractionating the extract. That is, the extract refers to the liquid component obtained by immersing the target substance in various solvents and then extracting for a certain period of time at room temperature, low temperature or high temperature, and the solid component obtained by removing the solvent from the liquid component. In addition to the above results, it can be comprehensively interpreted to include dilutions of the above results, their concentrates, their adjusted products, purified products, etc.
[0051] For example, fractions obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, and fractions obtained through various purification methods such as separation by chromatography are also included in the extract of this application.
[0052] The method for extracting the extract of the zelkova tree in this application is not particularly limited, and extraction can be performed according to methods commonly used in the relevant technical field. These include hot water extraction, ultrasonic extraction, filtration, and reflux extraction, and these can be performed alone or in combination of two or more methods, but are not limited thereto.
[0053] The type of extraction solvent used for extraction in the present application is not particularly limited, and any solvent known in the art can be used. As the extraction solvent, water or distilled water; alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, butyl alcohol, etc.; polyhydric alcohols such as glycerin, butylene glycol, propylene glycol, etc.; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, dichloromethane, etc.; or mixtures thereof can be used, but are not limited thereto. In addition, a solvent extract can be prepared by extraction one or more times using the solvent, and a dried extract obtained by distilling the solvent extract under reduced pressure and then freeze-drying or spray-drying can be prepared.
[0054] Specifically, water can be used as a solvent for the preparation of the extract in the present application.
[0055] In one embodiment of the present application, the step of preparing the extract of the zelkova tree may be to mix the powder of the zelkova tree and the solvent at a ratio of 1:5 to 1:30 and extract, and specifically, the powder of the zelkova tree and the solvent may be mixed at a ratio of 1:5 or more, 1:7 or more, 1:10 or more, 1:12 or more, 1:15 or more, 1:30 or less, 1:29 or less, 1:28 or less, 1:27 or less, 1:26 or less, or 1:25 or less and extract. More specifically, the extract may be to mix the powder of the zelkova tree and the solvent at a ratio of 1:13, 1:14, 1:15, 1:16, 1:18, 1:20, 1:22, or 1:24 and extract.
[0056] The above extraction temperature may be 80℃ or higher, 82℃ or higher, 83℃ or higher, 84℃ or higher, 85℃ or higher, 86℃ or higher, 87℃ or higher, 88℃ or higher, 89℃ or higher, 90℃ or higher, 91℃ or higher, 92℃ or higher, 93℃ or higher, 94℃ or higher, 95℃ or higher, 120℃ or lower, 119℃ or lower, 118℃ or lower, 117℃ or lower, 116℃ or lower, 115℃ or lower, 114℃ or lower, 113℃ or lower, 112℃ or lower, 111℃ or lower, 110℃ or lower, 109℃ or lower, 109℃ or lower, 108℃ or lower, 107℃ or lower, 106℃ or lower, 105℃ or lower, and 96℃, 97℃, 98℃, 99℃, 100℃, It can be 101℃, 102℃, 103℃, or 104℃.
[0057] The above extraction time may be 2 hours or more, 3 hours or more, 4 hours or more, 5 hours or more, 12 hours or less, 10 hours or less, 8 hours or less, or 7 hours or less.
[0058] According to these extraction conditions, the component exhibiting the effect desired in the present invention can be efficiently extracted from the above raw material.
[0059] The above-mentioned prepared extract can then be filtered, concentrated, or dried to remove the solvent. Filtration, concentration, and drying can all be performed. For example, filtration can be performed using filter paper or a vacuum filter, concentration can be performed using a vacuum concentrator, and drying can be performed using a freeze-drying method, but the present invention is not limited thereto.
[0060] In this application, the term “fraction” means a result obtained by a fractionation method for separating a specific component or a specific group from a mixture containing various components.
[0061] In the present application, the fractions can be interpreted as fractions obtained by applying the extract of the zelkova tree to various fractionation methods. The fractions of the extract can be obtained by applying the extract to various fractionation methods, and the fractionation methods are not particularly limited thereto, but may include, but are not limited to, solvent fractionation methods performed by treating various solvents, ultrafiltration fractionation methods performed by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, or chromatographic fractionation methods performed by performing various chromatographies (designed for separation according to size, charge, hydrophobicity, or affinity).
[0062] In particular, the solvent used in the solvent fractionation method is not particularly limited thereto, but a polar solvent or a non-polar solvent may be used, and specifically, a non-polar solvent may be used. The solvent fractionation method may be performed by sequentially fractionating the extract using a solvent with a high degree of non-polarity to a solvent with a low degree of non-polarity. For example, a method of sequentially fractionating the extract using hexane or ethyl acetate may be used. The fractionation solvent may be a polar solvent such as water, distilled water, or alcohol; or a non-polar solvent such as hexane, ethyl acetate, chloroform, or dichloromethane, and these may be used alone or in combination of two or more, but are not limited thereto.
[0063] The present application provides a method for preparing a pharmaceutical composition for preventing or treating cancer, which comprises a fermented product of the zelkova tree as an active ingredient.
[0064] The present application provides a pharmaceutical composition for preventing or treating cancer, which contains a lactic acid bacteria fermented extract of a Japanese yam tree as an active ingredient.
[0065] The above pharmaceutical composition may include a fermented product of the zelkova tree or a fraction thereof.
[0066] The term "fermentation" in this application refers to the decomposition of organic matter using enzymes possessed by microorganisms. In this application, an extract of the Korean zelkova tree can be fermented using lactic acid bacteria.
[0067] The above lactic acid bacteria may be at least one selected from the group consisting of Lactobacillus plantarum, Lacticazeibacillus rhamnosus, and Lactiplantibacillus pentosus strains. The above lactic acid bacteria may be used as a strain for fermentation, but may also function as included in the final product, the extract.
[0068] In this application, the term "fermented product" means a process of physically and chemically denaturing or transforming raw materials using lactic acid bacteria, and refers to a decomposition process that can obtain a desired result in just a few hours or days, something that would take tens of thousands of years to change in nature. Specifically, the fermented product may be a fermented product produced by inoculating and fermenting a lactic acid bacteria-inoculated zelkova extract. The zelkova fermented product may not only refer to a product fermented by lactic acid bacteria of a zelkova extract, but may also include a fermented filtrate obtained by fermenting a zelkova tree with lactic acid bacteria and then filtering it, or a fermented extract obtained by extracting a zelkova fermented product with a solvent.
[0069] In the present application, the term "fermented extract" may refer to a useful substance itself produced by fermenting the extract of the zelkova tree using lactic acid bacteria, and may include all of a microbial culture medium in which lactic acid bacteria and the fermented extract coexist, a fermented extract obtained by removing lactic acid bacteria from the culture medium by centrifugation, a fermented extract obtained by filtering lactic acid bacteria from the culture medium, a fermented extract obtained by sterilizing lactic acid bacteria from the culture medium and filtering the same, a diluted solution obtained by diluting the fermented extract, or a dried product obtained by drying the fermented extract. In the process of fermenting and extracting the zelkova tree, it may include both fermentation followed by extraction, or extraction followed by fermentation.
[0070] In one embodiment of the present application, in the step of inoculating the lactic acid bacteria culture solution into the extract of the zelkova tree and fermenting it to obtain a fermented product, the fermentation temperature may be 25°C to 40°C, 30°C to 38°C, or 35°C to 37°C. The fermentation time may be 1 to 6 days, 2 to 5 days, or 2 to 4 days.
[0071] The fermented product of the above-mentioned tree may be included in the composition at a concentration of 0.1 μg / ml to 200 μg / ml. More specifically, it may be 0.5 μg / ml to 150 μg / ml, and even more specifically, it may be 1 μg / ml to 100 μg / ml. If the concentration is less than 0.1 μg / ml, the effect is minimal, and if it is included at a concentration exceeding 200 μg / ml, it may exhibit toxicity to tissue cells other than cancer cells.
[0072] The term "cancer" in this application generally refers to or describes a physiological condition in mammals characterized by uncontrolled cell growth. "Cancer" refers to a condition in which abnormal cell proliferation occurs due to a disruption in the normal regulation of cell division, differentiation, and death, infiltrating surrounding tissues and organs, forming masses, and destroying or distorting existing structures.
[0073] The above cancers include breast cancer, pancreatic cancer, colon cancer, ovarian cancer, stomach cancer, cervical cancer, thyroid cancer, parathyroid cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, bile duct cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head and neck cancer, uterine cancer, rectal cancer, brain cancer, anal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine cancer, endocrine cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureteral cancer, renal cell carcinoma, renal pelvic carcinoma, blood cancer, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic It may be at least one selected from the group consisting of leukemia, central nervous system (CNS) tumor, spinal cord tumor, brainstem glioma, and pituitary adenoma.
[0074] The composition according to the present application may comprise a pharmaceutically effective amount of fermented zelkova tree alone or may comprise one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, improve, and treat cancer.
[0075] In addition, the term "pharmaceutically acceptable" as used above refers to a composition that is physiologically acceptable and does not typically cause allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to humans. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil. In addition, the composition may further include, but is not limited to, pharmaceutically acceptable fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, analgesics, isotonic agents, preservatives and other auxiliary agents.
[0076] In the form of such pharmaceutical preparations, the present application can be administered in various oral and parenteral dosage forms during actual clinical administration. Solid preparations for oral administration may include tablets, pills, powders, granules, or capsules. In addition, liquid preparations for oral administration include suspensions, oral solutions, emulsions, or syrups, and preparations for parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, or topical application) include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, or suppositories, but can be appropriately selected by those skilled in the art.
[0077] Additionally, the composition of the present application can be formulated using methods known in the art to provide rapid, sustained, or delayed release of the active ingredient after administration to a mammal. The formulation can be in the form of a powder, granules, tablets, emulsions, syrups, aerosols, soft gelatin capsules, hard gelatin capsules, sterile injectable solutions, or sterile powders.
[0078] The composition for preventing and treating cancer according to the present application may be administered via various routes, including orally, transdermally, subcutaneously, intravenously, or intramuscularly. The dosage of the active ingredient may be appropriately selected based on various factors, such as the route of administration, the patient's age, sex, weight, and the severity of the condition. Furthermore, the composition for preventing and treating cancer according to the present application may be administered in combination with compounds that have the effect of preventing, improving, or treating cancer.
[0079] The present application provides a food composition for preventing or improving cancer, which contains a lactic acid bacteria fermented extract of the zelkova tree as an active ingredient.
[0080] The above food composition may include a health functional food. The term "health functional food" is the same as "food for special health use (FoSHU)," and refers to a food with high medical and therapeutic effects that is processed to efficiently exhibit a bioregulatory function in addition to providing nutrition. The "function" refers to obtaining a useful effect for health purposes, such as regulating nutrients for the structure and function of the human body or physiological action. The health functional food of the present application can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and ingredients commonly added in the art during the manufacture of the health functional food. In addition, the formulation of the health functional food can be manufactured without limitation as long as it is a formulation recognized as a food. The health functional food composition of the present application can be manufactured in various forms, and unlike general drugs, it does not have side effects that may occur with long-term use of drugs because it uses food as a raw material, and has the advantage of excellent portability.
[0081] There are no restrictions on the form that the health functional food of this application can take. It can include all foods in their conventional sense, and can be used interchangeably with terms known in the art, such as functional food. Furthermore, the health functional food of this application can be manufactured by mixing other appropriate auxiliary ingredients and known additives that can be included in foods, at the discretion of those skilled in the art. Examples of foods to which the health functional food of this application can be added include various foods, beverages, gum, tea, vitamin complexes, and functional foods. Additionally, in the present application, food includes, but is not limited to, special nutritional foods (e.g., formula milk, infant / toddler food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), bread, health supplements, seasoned foods (e.g., soy sauce, soybean paste, red pepper paste, mixed paste, etc.), sauces, confectionery (e.g., snacks), candies, chocolates, gums, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi, pickled vegetables, etc.), beverages (e.g., fruit drinks, vegetable drinks, soy milk, fermented drinks, etc.), or natural seasonings (e.g., ramen soup, etc.). The above foods, beverages, or food additives can be manufactured by a conventional manufacturing method.
[0082] Furthermore, in addition to those described above, a food containing the composition for preventing and improving cancer of the present application may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, carbonating agents used in alcoholic or carbonated beverages, etc., and the above components may be used independently or in combination.
[0083] Additionally, the health functional food composition of the present application may additionally include a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier commonly used in the art may be used. Furthermore, the health functional food composition may include, without limitation, additional ingredients commonly used in food compositions to enhance odor, taste, appearance, etc., and these may be selected and used in an appropriate amount depending on the type of food.
[0084] One embodiment of the present application provides a feed composition for preventing or improving cancer, comprising a lactic acid bacteria fermented extract of a Japanese yam tree or a fraction thereof as an active ingredient.
[0085] The above feed composition may include feed additives. The feed additives of the present application fall under the category of supplementary feed under the Feed Management Act.
[0086] In this application, the term "feed" means any natural or artificial diet, meal, etc. or a component of said meal, intended for or suitable for eating, ingesting and digesting by an animal.
[0087] The type of the above feed is not particularly limited, and feed commonly used in the relevant technical field can be used. Non-limiting examples of the above feed include plant feed such as grains, dried fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils, starches, meal, or grain by-products; and animal feed such as proteins, inorganic substances, oils, minerals, oils, single-cell proteins, zooplankton, or food. These may be used alone or in combination of two or more.
[0088] The term "feed additive" in this application includes substances added to feed for various purposes such as nutritional supplementation and prevention of weight loss, promotion of digestibility and utilization of fiber in feed, improvement of milk quality, prevention of reproductive disorders and improvement of conception rate, and prevention of summer heat stress. The feed additive of this application corresponds to supplementary feed under the Feed Management Act of the Republic of Korea, and may additionally include mineral preparations such as sodium bicarbonate, bentonite, magnesium oxide, and complex minerals; mineral preparations that are trace minerals such as zinc, copper, cobalt, and selenium; vitamins such as carotene, vitamin A, vitamin D, vitamin E, nicotinic acid, and vitamin B complex; protected amino acids such as methionine and lysine; protected fatty acids such as fatty acid calcium salts; probiotics (lactic acid bacteria), yeast cultures, and mold fermentations; and yeast agents.
[0089] One embodiment of the present application provides a pharmaceutical composition for preventing or improving cancer, comprising a lactic acid bacteria fermented extract of a Japanese yam tree or a fraction thereof as an active ingredient.
[0090] In the specification of this application, the term "quasi-drug" means a product that has a milder effect than a pharmaceutical product among products used for the purpose of diagnosing, treating, improving, alleviating, managing or preventing diseases of humans or animals. For example, according to the Pharmaceutical Affairs Act of the Republic of Korea, a quasi-drug means a product other than a product used for the purpose of a pharmaceutical product.
[0091] Non-medicinal products are products that fall under any of the following categories: fibers, rubber products, or similar products used for the purpose of treating, alleviating, managing, or preventing diseases of humans or animals; products that have a weak effect on the human body or do not directly affect the human body and are not devices or machines; preparations used for sterilization, insecticide, and similar purposes to prevent infection; and products that are used for the purpose of diagnosing, treating, alleviating, managing, or preventing diseases of humans or animals, excluding products that are not devices, machines, or devices, and products that are used for the purpose of exerting a pharmacological effect on the structure and function of humans or animals, excluding products that are not devices, machines, or devices. They also include external preparations and personal hygiene products.
[0092] When the composition of the present application is used as a quasi-drug composition, the fermented product of the Korean zelkova tree can be added as is or used appropriately in combination with other quasi-drug ingredients according to conventional methods. The amount of active ingredient mixed can be appropriately determined depending on the intended use.
[0093] The contents of the pharmaceutical composition or health functional food composition may be applied to the pharmaceutical composition of the present application.
[0094] In addition, the composition may further include additives such as fragrances, pigments, sterilizers, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers, or synthetic polymers to improve physical properties, but is not limited thereto.
[0095] One embodiment of the present application provides a method for preventing or treating cancer, comprising administering to a subject other than a human a pharmaceutical composition comprising a fermented product of the zelkova tree or a fraction thereof as an active ingredient.
[0096] The term "subject" in this application means any animal that is likely to develop cancer or has developed cancer.
[0097] The feed composition according to the present application can be applied to any non-human animal for the purpose of improving, preventing, or alleviating cancer, without limitation. For example, it can be applied to any non-human animal, such as dogs, cats, monkeys, rabbits, guinea pigs, rats, mice, cows, sheep, pigs, or goats, as well as birds and fish.
[0098] One embodiment of the present application provides the use of a composition comprising a lactic acid bacteria fermented extract of the deciduous tree as an active ingredient for preparing a medicament for preventing or treating cancer.
[0099] The lactic acid bacteria fermented extract of the zelkova tree is the same as described above, so a detailed description is omitted.
[0100]
[0101] Hereinafter, the present invention will be described in detail through examples and comparative examples. However, the following examples and comparative examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.
[0102]
[0103] <Manufacturing Example> Manufacturing of fermented zelkova tree
[0104] The leaves and stems of the Japanese maple were dried in the shade, then ground and powdered. The powder used was 100% powder of the leaves and stems.
[0105] Lactic acid bacteria, including Lactobacillus plantarum (KCTC 3105), Lacticaseibacillus rhamnosus (KACC 11953), and Lactiplantibacillus pentosus (KACC 17113), were used from the Korea Research Institute of Bioscience and Biotechnology (KCTC) and the National Institute of Agricultural Sciences (KACC) Seed Bank (KACC) of the Rural Development Administration. The lactic acid bacteria strains were prepared in a medium according to Table 1 below in an incubator controlled at 37°C, autoclaved at 121°C for 15 minutes, and subcultured for 2 to 4 generations before use. The strains were spread on a sterilized solid medium, cultured for 24 hours, and inoculated into a liquid medium. The lactic acid bacteria culture solution cultured for 24 hours in an incubator controlled at 37°C was used in the fermented product of Japanese yam.
[0106] LactoBacilli MRS Broth (BD Difco™ 288130) Ingredient Nameg / LProteose Peptone No. 310Beef extract10Yeast extract5Dextrose20Polysorbate 801Ammonium Citrate2Sodium Acetate5Magnesium Sulfate0.1Manganese Sulfate0.05Dipotassium Phosphate2
[0107] First, a mixture of 1:20 ratio of zelkova powder and distilled water was mixed, and then hot water extracted at 100°C for 6 hours to prepare an extract. 1% of the above lactic acid bacteria culture was inoculated into the hot water extract, and then fermented at 37°C for 48 hours. After fermentation, the extract was autoclaved at 121°C for 15 minutes to inactivate the lactic acid bacteria strain, and the fermented product was prepared by filtering it with a 3 μm filter. At this time, the concentration of the fermented product was varied to prepare Examples 1 to 6, respectively.
[0108]
[0109] <Comparative Example>
[0110] After mixing the powder of the Japanese cypress tree and 95% ethanol in a ratio of 1:20, the mixture was refluxed and extracted at 65°C for 6 hours. After extraction, the extract was filtered through a 3 μm sieve, and the concentration of the extract was set to 50 μg / ml to prepare Comparative Example 1.
[0111] Lactobacillus acidophilus (KACC 12419) was obtained from the Seed Bank of the National Institute of Agricultural Sciences (KACC). The strain was used after preparing a medium according to Table 1 in an incubator regulated at 37°C, autoclaving at 121°C for 15 minutes, and subculturing for 2 to 4 generations. The strain was spread on a sterilized solid medium, cultured for 24 hours, and inoculated into a liquid medium. The culture solution, cultured for 24 hours in an incubator regulated at 37°C, was used for fermenting the zelkova tree.
[0112] The method for producing fermented products of the Korean fir tree was the same as that described in the above manufacturing example. In this case, L. acidophilus was used as the lactic acid bacteria, and comparative examples 2 and 3 were produced by varying the concentration of the fermented products.
[0113]
[0114] <Experimental Example 1> Measurement of apoptotic efficacy against blood cancer cells
[0115] 1. Culturing of blood cancer cells (Molt-4)
[0116] Blood cancer cells (Molt-4, KCLB 21582) were obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea). RPMI 1640 (SH30027.01, Cytiva, USA) containing 10% Fetal Bovine Serum (FBS, Gibco, CA, USA) medium, 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), and 25 mM NaHCO3 was used as the medium. Cells were subcultured for 2 to 5 generations in an incubator controlled at 95% humidity, 25% CO2, and 37°C, and medium antibiotics (Penicillin streptomycin, Gibco, CA, USA) were used to suppress microbial contamination or proliferation. For cell subculture, cells were washed with phosphate-buffered saline (PBS, pH 7.4, Thermo Fisher Scientific, Massachusetts, USA), treated with Trypsin-EDTA (Gibco, Thermo Fisher Scientific, Massachusetts, USA), detached, and cultured by exchanging the medium every 48 to 72 hours.
[0117] 2. Measurement of the apoptotic efficacy of Molt-4 cells
[0118] Molt-4 cell line and Examples 1 to 3 and Comparative Examples 1 and 2 were dispensed into a 96-well plate and cultured at 95% humidity, 25% CO2, and 37°C for 24 hours.
[0119] Cell line viability was measured using MTS (CellTiter 96 ®The viability of cells was measured using the Aqueous One Solution Cell Proliferation Assay (Promega, USA). After reacting the cell line and the reagent at 37°C for 60 minutes, the absorbance was measured at 490 nm using a microplate reader (Molecular Devices, VersaMax ELISA Microplate Reader, USA). After treating the cells with Examples 1 to 3 and Comparative Examples 1 and 2, the viability of the cells was expressed as absorbance.
[0120] The results of the experiment on the killing efficacy of Molt-4 cells by fermented products of the zelkova tree and ethanol extract are shown in Table 2 and Figure 1 below.
[0121]
[0122] Strain concentration (㎍ / ml) Molt-4 cell viability (%) Control group--100.0 ± 2.5 Example 1 L. plantarum 50 4 1.1 ± 6.1 Example 2 L. rhamnosus 50 4 0.9 ± 4.9 Example 3 L. pentosus 50 5 0.6 ± 6.4 Comparative example 1-50 7 8.4 ± 5.9 Comparative example 2 L. acidophilus 50 9 4.3 ± 2.4
[0123] Referring to Table 2 and Figure 1, all of Examples 1 to 3 showed a blood cancer cell killing effect, and among them, Example 2, a fermented product of L. rhamnosus, showed the best effect in preventing or treating blood cancer.
[0124] In the case of comparative examples 1 and 2, it can be confirmed that the killing efficacy of Molt-4 cells is not good.
[0125]
[0126] <Experimental Example 2> Measurement of apoptotic efficacy against colon cancer cells
[0127] 1. Culturing of colon cancer cells (HT-29)
[0128] Colon cancer cells (HT-29, KCLB 30038) were obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea). RPMI 1640 (SH30027.01, Cytiva, USA) containing 10% Fetal Bovine Serum (FBS, Gibco, CA, USA) medium, 25 mM HEPES, and 25 mM NaHCO3 was used as the medium. Cells were subcultured for 2 to 5 generations in an incubator controlled at 95% humidity, 25% CO2, and 37°C. Medium antibiotics (Penicillin streptomycin, Gibco, CA, USA) were used to suppress microbial contamination and proliferation. For cell subculture, cells were washed with phosphate-buffered saline (PBS, pH 7.4, Thermo Fisher Scientific, Massachusetts, USA), treated with Trypsin-EDTA (Gibco, Thermo Fisher Scientific, Massachusetts, USA), detached, and cultured by exchanging the medium every 48 to 72 hours.
[0129] 2. Measurement of the apoptotic efficacy of HT-29 cells
[0130] HT-29 cell line and Examples 1 to 3 and Comparative Examples 1 and 2 were dispensed into a 96-well plate and cultured at 95% humidity, 25% CO2, and 37°C for 24 hours.
[0131] Cell line viability was measured using MTS (CellTiter 96 ®The viability of cells was measured using the Aqueous One Solution Cell Proliferation Assay reagent (Promega, USA). After reacting the cell line and the reagent at 37°C for 60 minutes, the absorbance was measured at 490 nm using a microplate reader (Molecular Devices, VersaMax ELISA Microplate Reader, USA). After treating the cells with Examples 1 to 3 and Comparative Example 2, the viability of the cells was expressed as absorbance.
[0132] The results of the experiment on the apoptotic efficacy of fermented products of the Korean ash tree and ethanol extract on HT-29 cells are shown in Table 3 and Figure 2 below.
[0133]
[0134] Strain concentration (㎍ / ml) HT-29 cell viability (%) Control group--100.0 ± 3.1 Example 1 L. plantarum 50 78.4 ± 11.1 Example 2 L. rhamnosus 50 76.5 ± 11.9 Example 3 L. pentosus 50 73.3 ± 9.1 Comparative example 2 L. acidophilus 50 110.7 ± 4.5
[0135] Referring to Table 3 and Figure 2, all of Examples 1 to 3 showed colon cancer cell killing effects, and among them, Example 3, a fermented product of L. pentosus, showed the best effect in preventing or treating colon cancer.
[0136] On the other hand, in the case of comparative example 2, colon cancer cells rather proliferated.
[0137]
[0138] <Experimental Example 3> Measurement of apoptotic efficacy against breast cancer cells
[0139] 1. Culturing of breast cancer cells (MCF-7)
[0140] Breast cancer cells (MCF-7, KCLB30022) were obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea). Minimum essential medium (SH30024.01, Cytiva, USA) containing 10% Fetal Bovine Serum (FBS, Gibco, CA, USA), 25 mM HEPES, and 25 mM NaHCO3 was used as the medium. Cells were subcultured for 2 to 5 generations in an incubator controlled at 95% humidity, 25% CO2, and 37°C. Medium antibiotics (Penicillin streptomycin, Gibco, CA, USA) were used to suppress microbial contamination and proliferation. For cell subculture, cells were washed with phosphate-buffered saline (PBS, pH 7.4, Thermo Fisher Scientific, Massachusetts, USA), treated with Trypsin-EDTA (Gibco, Thermo Fisher Scientific, Massachusetts, USA), detached, and cultured by exchanging the medium every 48 to 72 hours.
[0141] 2. Measurement of the apoptotic efficacy of MCF-7 cells
[0142] MCF-7 cell line and Examples 4 to 6 and Comparative Example 4 were dispensed into a 96-well plate and cultured at 95% humidity, 25% CO2, and 37°C for 24 hours.
[0143] Cell line viability was measured using MTS (CellTiter 96 ®The viability of cells was measured using the Aqueous One Solution Cell Proliferation Assay (Promega, USA). After reacting the cell line and the reagent at 37°C for 60 minutes, the absorbance was measured at 490 nm using a microplate reader (Molecular Devices, VersaMax ELISA Microplate Reader, USA). After treating the cells with Examples 4 to 6 and Comparative Example 3, the viability of the cells was expressed as absorbance.
[0144] The results of the experiment on the apoptotic efficacy of fermented products of the Korean ash tree and ethanol extract on MCF-7 cells are shown in Table 4 and Figure 3 below.
[0145] Strain concentration (㎍ / ml) MCF-7 cell viability (%) Control group--100.0 ± 2.3 Example 4 L. plantarum 100 6 7.2 ± 1.6 Example 5 L. rhamnosus 100 7 9.6 ± 1.4 Example 6 L. pentosus 100 7 9.5 ± 2.3 Comparative example 3 L. acidophilus 100 9 6.1 ± 9.1
[0146] Referring to Table 4 and Figure 3, all of Examples 4 to 6 showed a breast cancer cell killing effect, and among them, Example 4, which is a fermented product of L. plantarum, showed the best effect in preventing or treating breast cancer.
[0147] In the case of Comparative Example 3, it can be confirmed that the killing efficacy of MCF-7 cells is lower than that of the example.
[0148]
[0149] <Experimental Example 4> Measurement of apoptotic efficacy against pancreatic cancer cells
[0150] 1. Culturing of pancreatic cancer cells (MIA PaCa-2)
[0151] Pancreatic cancer cells (MIA PaCa-2, KCLB 21420) were obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea). DMEM High Glucose (SH30243.01, Cytiva, USA) containing 10% Fetal Bovine Serum (FBS, Gibco, CA, USA) was used as the medium. Cells were subcultured for 2 to 5 generations in an incubator controlled at 95% humidity, 25% CO2, and 37°C. Medium antibiotics (Penicillin streptomycin, Gibco, CA, USA) were used to suppress microbial contamination or proliferation. For cell subculture, cells were washed with phosphate-buffered saline (PBS, pH 7.4, Thermo Fisher Scientific, Massachusetts, USA), treated with Trypsin-EDTA (Gibco, Thermo Fisher Scientific, Massachusetts, USA), detached, and cultured by exchanging the medium every 48 to 72 hours.
[0152] 2. Measurement of the apoptotic efficacy of MIA PaCa-2 cells
[0153] MIA PaCa-2 cell line and Examples 4 to 6 and Comparative Example 3 were dispensed into a 96-well plate and cultured at 95% humidity, 25% CO2, and 37°C for 24 hours.
[0154] Cell line viability was measured using MTS (CellTiter 96 ®Cell viability was measured using the AQueous One Solution Cell Proliferation Assay (Promega, USA). After reacting the cell line and the reagent at 37°C for 60 minutes, the absorbance was measured at 490 nm using a microplate reader (Molecular Devices, VersaMax ELISA Microplate Reader, USA). After treating the cells with Examples 4 to 6 and Comparative Example 3, the cell viability was expressed as absorbance.
[0155] The results of the experiment on the apoptotic efficacy of fermented products of the Korean magnolia tree and ethanol extract on MIA PaCa-2 cells are shown in Table 5 and Figure 4 below.
[0156] Strain concentration (㎍ / ml) MIA PaCa-2 cell viability (%) Control group--100.0 ± 1.7 Example 4 L. plantarum 100 5 6.6 ± 9.6 Example 5 L. rhamnosus 100 5 8.1 ± 3.1 Example 6 L. pentosus 100 7 2.0 ± 1.9 Comparative example 3 L. acidophilus 100 8 7.8 ± 6.7
[0157] Referring to Table 5 and Figure 4, all of Examples 4 to 6 showed a pancreatic cancer cell killing effect, and among them, Example 4, a fermented product of L. plantarum, showed the best effect in preventing or treating pancreatic cancer.
[0158] In the case of Comparative Example 3, it can be confirmed that the killing efficacy of MIA PaCa-2 cells is not good.
[0159] While specific portions of this application have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and are not intended to limit the scope of this application. Therefore, the substantial scope of this application is defined by the appended claims and their equivalents. Furthermore, various modifications and improvements made by those skilled in the art utilizing the basic concepts of this application defined in the claims are also within the scope of this application.
Claims
1. A step for preparing an extract of the zelkova tree; and A method for producing a pharmaceutical composition for preventing or treating cancer, comprising the steps of inoculating the above extract with a lactic acid bacteria culture solution and fermenting it to obtain a fermented product; A method for producing a pharmaceutical composition for preventing or treating cancer, characterized in that the pharmaceutical composition comprises the fermented product as an active ingredient.
2. In claim 1, The above lactic acid bacteria are, A method for producing a pharmaceutical composition for preventing or treating cancer, characterized in that it comprises at least one selected from the group consisting of Lactobacillus plantarum, Lacticaseibacillus rhamnosus, and Lactiplantibacillus pentosus.
3. In claim 1, In the step of obtaining the above fermented product, A method for producing a pharmaceutical composition for preventing or treating cancer, characterized in that the fermentation is performed at 30°C to 37°C for 1 to 6 days.
4. In claim 1, The steps for manufacturing the above extract of the zelkova tree are as follows: A method for producing a pharmaceutical composition for preventing or treating cancer, characterized in that the powder of the zelkova tree and the solvent are mixed and extracted in a ratio of 1:5 to 1:
30.
5. In claim 1, The above-mentioned tree is at least one of a leaf and a stem, A method for producing a pharmaceutical composition for preventing or treating cancer, characterized in that the extract is an extract extracted with hot water at 80°C to 110°C for 2 to 12 hours.
6. In claim 1, The above cancer, Breast cancer, pancreatic cancer, colon cancer, ovarian cancer, stomach cancer, cervical cancer, thyroid cancer, parathyroid cancer, lung cancer, non-small cell lung cancer, prostate cancer, gallbladder cancer, bile duct cancer, bladder cancer, kidney cancer, melanoma, colon cancer, bone cancer, skin cancer, head and neck cancer, uterine cancer, rectal cancer, brain cancer, anal cancer, fallopian tube carcinoma, endometrial carcinoma, vaginal cancer, vulvar carcinoma, esophageal cancer, small intestine cancer, endocrine cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, ureteral cancer, renal cell carcinoma, renal pelvic carcinoma, blood cancer, acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, A method for preparing a pharmaceutical composition for preventing or treating cancer, characterized in that it is at least one selected from the group consisting of central nervous system (CNS) tumors, spinal cord tumors, brainstem gliomas, and pituitary adenomas.
7. Manufactured by any one of the manufacturing methods of claims 1 to 6, A pharmaceutical composition for preventing or treating cancer, comprising a lactic acid bacteria fermented extract of a Korean poplar tree as an active ingredient.
8. A food composition for preventing or improving cancer, containing a lactic acid bacteria fermented extract of a Korean maple tree as an active ingredient.
9. A feed composition for preventing or improving cancer, containing a fermented lactic acid bacteria extract of the zelkova tree as an active ingredient.
10. A pharmaceutical composition for preventing or improving cancer, containing a lactic acid bacteria fermented extract of the deciduous tree as an active ingredient.
11. A method for preventing or treating cancer, comprising administering to a subject a pharmaceutical composition according to any one of claims 1 to 6.
12. Use of a composition manufactured by the manufacturing method of any one of claims 1 to 6 for manufacturing a drug for preventing or treating cancer, and containing a lactic acid bacteria fermented extract of the zelkova tree as an active ingredient.
Citation Information
Patent Citations
Fermented fruit and Anti-cancer pharmaceutical composition containing the same
KR100759773B1
Method of fermenting mushroom using lactic acid, and lactic acid fermentate of mushroom prepared thereby
KR1020030042307A
A method of manufacturing multi-component alloy catalyst
KR1020200116806A
